HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEA safety document

This article was originally published in The Rose Sheet

Executive Summary

National Toxicity Program releases background documents for four nominations under consideration for inclusion in the 11th "Report on Carcinogens," including diethanolamine, according to a notice published in the May 24 1Federal Register. Documents are available through the NTP Web site at 2http://ntp-server.niehs.nih.gov. CTFA asserted in Sept. 17, 2001 comments to NTP that existing test data on DEA do not meet NTP criteria for determining ingredients are "reasonably anticipated to be" human carcinogens (3"The Rose Sheet" Oct. 1, 2001, p. 8). Background documents for other nominations including cobalt sulfate, nitromethane and 4, 4-thiodianiline also now available...

You may also be interested in...



DEA Cosmetics Use, Carcinogenicity Potential Explored In NTP Report

Consumer exposure to diethanolamine appears to be widespread with dermal exposure to personal care products serving as the "most probable route," the National Toxicology Program states in a background draft document for the 11th "Report on Carcinogens.

DEA Carcinogenicity Evidence Limited To "One Study, One Species" - CTFA

Animal data indicating diethanolamine may be a human carcinogen are limited to "one study in one species, with...one route of exposure," the Cosmetic, Toiletry and Fragrance Association maintains in Sept. 17 comments to the National Toxicology Program.

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

UsernamePublicRestriction

Register

RS010312

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel